Введение

urmj

Уральский медицинский журнал

Ural Medical Journal

2949-4389

Ural State Medical University

10.52420/2071-5943-2023-22-3-96-107

urmj-1275

Research Article

Литературные обзоры | Literature reviews

Literature reviews

Роль урокиназы, Т-кадгерина и адипонектина в развитии эндогенных депрессивных расстройств

The role of urokinase, T-cadherin and adiponetin in the development of endogenous depressive disorders

https://orcid.org/0000-0002-2903-4664

Шелег

Д. А.

Sheleg

D. A.

Дмитрий Александрович Шелег – аспирант

Москва

Dmitrij A. Sheleg – Postgraduate student

Moscow

sheleg-da@mail.ru

https://orcid.org/0000-0003-4289-3428

Карагяур

М. Н.

Karagyaur

M. N.

Максим Николаевич Карагяур – кандидат биологических наук

Москва

Maksim N. Karagyaur – Ph.D. in biology

Moscow

m.karagyaur@mail.ru

https://orcid.org/0000-0002-1386-5922

Примак

А. Л.

Primak

A. L.

Александра Леонидовна Примак – лаборант-исследователь

Москва

Aleksandra L. Primak – Research Laboratory Assistant

Moscow

primak.msu@mail.ru

https://orcid.org/0000-0003-2647-1284

Нейфельд

Е. А.

Neyfeld

E. A.

Елена Арсланалиевна Нейфельд – кандидат медицинских наук

Москва

Elena A. Neyfeld – Ph.D. in medicine

Moscow

ea.neyfeld@mail.ru

Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation

Московский государственный университет им. М.В. ЛомоносоваРоссияLomonosov Moscow State UniversityRussian Federation

2023

03072023

22396107

2023

Шелег Д.А., Карагяур М.Н., Примак А.Л., Нейфельд Е.А.

Sheleg D.A., Karagyaur M.N., Primak A.L., Neyfeld E.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.umjusmu.ru/jour/article/view/1275

Введение

Введение. Распространенность депрессии в среднем составляет примерно 6 % от всего населения. Наследуемость депрессии составляет от 28 % до 44 %. Генетическая предрасположенность может быть обусловлена полиморфизмами генов, участвующих в процессах функционирования и морфогенеза головного мозга: балансе моноаминов, действии навигационных молекул и их рецепторов.

Цель работы – определить роль генов, регулирующих процессы миграции нервных клеток и направленного роста нервных волокон навигационных рецепторов (PLAUR и CDH13) или их лигандов (PLAU, PLAT, ADIPOQ) в развитии эндогенной депрессии и шизофрении в российской популяции.

Материалы и методы

Материалы и методы. На первом этапе исследования был выполнен поиск научной литературы в базе данных MedLine. Первичная распространенность геномных вариантов будет установлена с помощью полногеномного секвенирования 20 пациентов с тяжелыми формами шизофрении и эндогенной депрессии. Далее в исследовании примут участие не менее 100 пациентов в каждой группе и 100 человек здоровых доноров.

Результаты и обсуждение

Результаты и обсуждение. Рецептор урокиназы (uPAR) участвует в нейрогенезе, регулируя траекторию роста аксонов. Уровень suPAR в плазме крови может выступать в роли биомаркера слабовыраженного воспаления, лежащего в этиологии депрессии. Уровень suPAR в плазме можно считать прогностическим фактором эффективности сочетанной терапии антидепрессантами и противовоспалительными препаратами. Молекулы суперсемейства кадгеринов участвуют в развитии нервной системы, передаче межклеточных сигналов и регулировании пластичности нервных клеток. Полиморфизмы генов CDH7, CDH9, CDH13, CDH17 демонстрируют корреляцию с наличием депрессии. Адипонектин – гормон, выделяемый жировой тканью. Один из рецепторов адипонектина, AdipoR2, стимулирует нейронную пластичность, ингибирует воспаление и оксидативный стресс. У пациентов с депрессией концентрация адипонектина в плазме снижается.

Заключение

Заключение. Накопленные исследователями результаты свидетельствуют в пользу важной роли uPAR и Т-кадгерина в процессах развития головного мозга, а главное в патогенезе развития эндогенных депрессий.

Introduction The prevalence of depression averages approximately 6 % of the total population. The heritability of depression ranges from 28 % to 44 %. Genetic predisposition may be due to polymorphisms of genes involved in the processes of functioning and morphogenesis of the brain: the balance of monoamines, the action of navigational molecules and their receptors.

Purpose of the study To determine the role of genes that regulate the processes of nerve cell migration and directed growth of nerve fibers of navigation receptors (PLAUR and CDH13) or their ligands (PLAU, PLAT, ADIPOQ) in the development of endogenous depression and schizophrenia in the Russian population.

Materials and methods At the first stage of the study, the scientific literature was searched in the MEDLINE database. The primary prevalence of genomic variants will be established using whole genome sequencing of 20 patients with severe forms of schizophrenia and endogenous depression. Further, at least 100 patients in each group and 100 healthy donors will take part in the study.

Results and discussion The urokinase receptor (uPAR) is involved in neurogenesis by regulating the trajectory of axonal growth. The level of suPAR in blood plasma can act as a biomarker of mild inflammation underlying the etiology of depression. The level of suPAR in plasma can be considered a predictor of the effectiveness of combination therapy with antidepressants and anti-inflammatory drugs. Molecules of the cadherin superfamily are involved in the development of the nervous system, the transmission of intercellular signals, and the regulation of neuronal plasticity. Polymorphisms of the CDH7, CDH9, CDH13, CDH17 genes demonstrate a correlation with the presence of depression. Adiponectin is a hormone secreted by adipose tissue. One of the adiponectin receptors, AdipoR2, stimulates neuronal plasticity and inhibits inflammation and oxidative stress. Plasma concentrations of adiponectin are reduced in depressed patients.

Conclusion The results accumulated by researchers testify in favor of the important role of uPAR and T-cadherin in the processes of brain development, and most importantly, in the pathogenesis of the development of endogenous depressions.

депрессияурокиназат-кадгеринадипонектин

depressionurokinaset-cadherinadiponectin

Внешнее финансирование при проведении исследования отсутствовало.

This study was not supported by any external sources of funding.

References1

Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. https://doi.org/10.1016/S01406736(18)31948-2.

Цыганков Б.Д., Овсянников С.А. Пограничная психиатрия и соматическая патология. М.: Триада; 2001. с. 23−24.

Tsygankov BD, Ovsyannikov SA. Borderline psychiatry and somatic pathology. Moscow: Triad; 2001. pp. 23−24. (In Russ.).

Lopez AD, Mathers CD, Ezzti M et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–1757. https://doi.org/10.1016/S0140-6736(06)68770-9.

Мосолов С.Н. Современные биологические гипотезы рекуррентной депрессии (обзор). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(11–2):29–40.

Mosolov SN. Current biological hypotheses of recurrent depression (review). S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2012;112(11–2):29–40. (In Russ.).

Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905.

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7.

Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Fail Clin. 2011;7(1):11–21. https://doi.org/10.1016/j.hfc.2010.08.003.

Cavanagh JTO, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol Med. 2003;33(3):395–405. https://doi.org/10.1017/s0033291702006943.

Goodwin F., Jamison K. Manic-depressive illness: bipolar disorders and recurrent depression. Oxford university press. 2007. pp. 419.

Fernandez-Pujals AM, Adams MJ, Thomson P et al. Epidemiology and heritability of major depressive disorder, stratified by age of onset, sex, and illness course in generation scotland: scottish family health study (GS:SFHS). PLoS One. 2015;10(11):e0142197. https://doi.org/10.1371/journal.pone.0142197.

Ventorp F, Gustaffson A, Träskman-Bendz L et al. Increased soluble urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters. PLoS One. 2015;10(10):e0140052. https://doi.org/10.1371/journal.pone.0140052.

Kessler RC, Nelson CB, McGonagle KA et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;30:17–30.

Insel T, Cuthbert B, Garvey M et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–751. https://doi.org/10.1176/appi.ajp.2010.09091379.

Ripke S, Wray NR, Lewis CM et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013;18(4):497–511. https://doi.org/10.1038/mp.2012.21.

Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology. 2021;46(1):156–175. https://doi.org/10.1038/s41386-020-00789-3.

Zisook S, Rush AJ, Lesser I et al. Preadult onset vs. adult onset of major depressive disorder: a replication study. Acta Psychiatr Scand. 2007;115(3):196–205. https://doi.org/10.1111/j.1600-0447.2006.00868.x.

Labonté B, Engmann O, Purushothaman I et al. Sex-specific transcriptional signatures in human depression. Nat Med. 2017;23(9):1102–1111. https://doi.org/10.1038/nm.4386.

Prathikanti S, Weinberger DR. Psychiatric genetics – the new era: genetic research and some clinical implications. Br Med Bull. 2005;73–74:107–122. https://doi.org/10.1093/bmb/ldh055.

Тиганов А.С., Снежневский А.В., Орловская Д.Д. Руководство по психиатрии. М. : Медицина ; 1999. с. 562−563. URL: http://www.psychiatry.ru/siteconst/userfiles/file/PDF/tiganov1.pdf

Tiganov AS, Snezhnevsky AV, Orlovskaya DD. Guide to Psychiatry. Moscow : Medicine ; 1999. pp. 562−563. (In Russ.) URL: http://www.psychiatry.ru/siteconst/userfiles/file/PDF/tiganov1.pdf

Корнилов В.А. Неблагоприятные исходы патологической реакции горя в позднем возрасте. Москва ; 2018. с 94. URL: https://www.ncpz.ru/siteconst/userfiles/file/diss/Kornilov/диссертация-корнилов.pdf

Kornilov VA. Adverse outcomes of the pathological reaction of grief in late adulthood. Moscow ; 2018. pp. 94. URL: https://www.ncpz.ru/siteconst/userfiles/file/diss/Kornilov/диссертация-корнилов.pdf

Вертоградова О.П., Кошкин К.А. Апатическая депрессия: структура и динамика. Социальная и клиническая психиатрия. 2010;20(2):26–32.

Vertogradova OP, Koshkin KA. Apathetic depression: structure and dynamics. Social and Clinical Psychiatry = Social’naja i klinicheskaja psihiatrija. 2010;20(2):26–32. (In Russ.).

Вертоградова О.П., Степанов И.Л., Максмова Н.М. с соавт. Клинико-патогенетические аспекты типологии депрессий. Социальная и клиническая психиатрия. 2012;22(3):5–10.

Vertogradova OP, Stepanov IL, Maksmova NM et al. Clinical and pathogenetic aspects of depression typology. Social and Clinical Psychiatry = Social’naja i klinicheskaja psihiatrija. 2012;22(3):5–10. (In Russ.).

Hasler G, Fromm S, Carlson PJ et al. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry. 2008;65(5):521–531. https://doi.org/10.1001/archpsyc.65.5.521.

Hasler G, van der Veen JW, Tumonis T et al. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193–200. https://doi.org/10.1001/archpsyc.64.2.193.

Beasley CL, Honer WG, Bergmann K et al. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord. 2005;7(5):449–455. https://doi.org/10.1111/j.1399-5618.2005.00239.x.

Kennedy SE, Koeppe RA, Young EA, Zubieta J-K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63(11):1199–1208. https://doi.org/10.1001/archpsyc.63.11.1199.

Goshen I, Kreisel T, Ben-Menachem-Zidon O et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. 2008;13(7):717–728. https://doi.org/10.1038/sj.mp.4002055.

Nielsen J, Røge R, Pristed SG et al. Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. Schizophr Bull. 2015;41(3):764–771. https://doi.org/10.1093/schbul/sbu118.

Семина Е.В., Рубина К.А., Степанова В.В., Ткачук В.А. Участие рецептора урокиназы и его эндогенных лигандов в развитии головного мозга и формировании когнитивных функций. Российский физиологический журнал им. И.М. Сеченова. 2016;102(8):881–903.

Semina EV, Rubina KA, Stepanova VV, Tkachuk VA. Participation of urokinase receptor and its endogenous ligands in brain development and formation of cognitive functions. Russian Journal of Physiology. 2016;102(8):881–903. (In Russ.).

Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. https://doi.org/10.1016/j.biopsych.2009.09.033.

Tonelli LH, Stiller J, Rujescu D et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand. 2008;117(3):198–206. https://doi.org/10.1111/j.1600-0447.2007.01128.x.

Małujło-Balcerska E., Kumor-Kisielewska A., Szemraj J., Pietras T. Serum uPAR concentration in patients with a depressive disorders – a preliminary study. Psychiatr Danub. 2022;34(1):104–105.

Dinesh P, Rasool M uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action. Pharmacol Res. 2018;134:31–39. https://doi.org/10.1016/j.phrs.2018.05.016.

Leth JM, Ploug M. Targeting the urokinase-type plasminogen activator receptor (uPAR) in human diseases with a view to non-invasive imaging and therapeutic intervention. Front Cell Dev Biol. 2021;9:732015. https://doi.org/10.3389/fcell.2021.732015.

Hawi Z, Tong J, Dark C et al. The role of cadherin genes in five major psychiatric disorders: A literature update. Am J Med Genet B Neuropsychiatr Genet. 2018;177(2):168–180. https://doi.org/10.1002/ajmg.b.32592.

Hirano S, Takeichi M. Cadherins in brain morphogenesis and wiring. Physiol Rev. 2012;92(2):597–634. https://doi.org/10.1152/physrev.00014.2011.

Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006;20(23):3199–3214. https://doi.org/10.1101/gad.1486806.

Seong E, Yuan L, Arikkath J. Cadherins and catenins in dendrite and synapse morphogenesis. Cell Adh Migr. 2015;9(3):202–213. https://doi.org/10.4161/19336918.2014.994919.

Rivero O, Selten MM, Sich S et al. Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition. Transl Psychiatry. 2015;5(10):e655. https://doi.org/10.1038/tp.2015.152.

Liu F-F, Zhang Z, Chen W et al. Regulatory mechanism of microRNA-377 on CDH13 expression in the cell model of Alzheimer’s disease. Eur Rev Med Pharmacol Sci. 2018;22(9):2801–2808. https://doi.org/10.26355/eurrev_201805_14979.

Li X, Wang Q, He K et al. Common variants in the CDH7 gene are associated with major depressive disorder in the Han Chinese population. Behav Genet. 2014;44(2):97–101. https://doi.org/10.1007/s10519-014-9645-y.

Xiao X, Zheng F, Chang H et al. The gene encoding Protocadherin 9 (PCDH9), a novel risk factor for major depressive disorder. Neuropsychopharmacology. 2018;43(5):1128–1137. https://doi.org/10.1038/npp.2017.241.

Ding Y, Chang L-C, Wang X et al. Molecular and genetic characterization of depression: overlap with other psychiatric disorders and aging. Mol Neuropsychiatry. 2015;1(1):1–12. https://doi.org/10.1159/000369974.

Hayashi S, Inoue Y, Kiyonari H et al. Protocadherin-17 mediates collective axon extension by recruiting actin regulator complexes to interaxonal contacts. Dev Cell. 2014;30(6):673–687. https://doi.org/10.1016/j.devcel.2014.07.015.

Chang H, Hoshina N, Zhang C et al. The protocadherin 17 gene affects cognition, personality, amygdala structure and function, synapse development and risk of major mood disorders. Mol Psychiatry. 2018;2(2):400–412. https://doi.org/10.1038/mp.2016.231.

de Luis DA, Izaolo O, Primo D et al. Role of rs1501299 variant in the adiponectin gene on total adiponectin levels, insulin resistance and weight loss after a Mediterranean hypocaloric diet. Diabetes Res Clin Pract. 2019;148:262–267. https://doi.org/10.1016/j.diabres.2017.11.007.

Bloemer J, Pinky PD, Govindarajulu M et al. Role of adiponectin in central nervous system disorders. Neural Plast. 2018;2018:4593530. https://doi.org/10.1155/2018/4593530.

Khoramipour K, Chamari K, Hekmatikar AA et al. Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition. Nutrients. 2021;13(4):1180. https://doi.org/10.3390/nu13041180.

Hug C, Wang J, Ahmad NS et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/ adiponectin. Proc Natl Acad Sci USA. 2004;101(28):10308–10313. https://doi.org/10.1073/pnas.0403382101.

Sun L-N, Liu X-L. Functions of adiponectin signaling in regulating neural plasticity and its application as the therapeutic target to neurological and psychiatric diseases. Rev Neurosci. 2019;30(5):485–495. https://doi.org/10.1515/revneuro-2018-0062.

Kubota N, Yano W, Kuboto T et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007;6(1):55–68. https://doi.org/10.1016/j.cmet.2007.06.003.

Wang Y, Lam KSL, Xu JX et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280(18):18341–18347. https://doi.org/10.1074/jbc.M501149200.

Zhang D, Wang X, Lu X-Y. Adiponectin exerts neurotrophic effects on dendritic arborization, spinogenesis, and neurogenesis of the dentate gyrus of male mice. Endocrinology. 2016;157(7):2853–2869. https://doi.org/10.1210/en.2015-2078.

Rizzo MR, Fasano R, Paolisso G. Adiponectin and cognitive decline. Int J Mol Sc. 2020;21(6):2010. https://doi.org/10.3390/ijms21062010.

Sun L, Li H, Gu P, Cheung CW. Adiponectin regulates thermal nociception in a mouse model of neuropathic pain. Br J Anaesth. 2018;120(6):1356–1367. https://doi.org/10.1016/j.bja.2018.01.016.

Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132(4):645–660. https://doi.org/10.1016/j.cell.2008.01.033.

Cassano T, Calcagnini S, Carbone A et al. Pharmacological treatment of depression in Alzheimer’s disease: a challenging task. Front Pharmacol. 2019;10:1067. https://doi.org/10.3389/fphar.2019.01067.

Liu J, Guo M, Zhang D et al. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci USA. 2012;109(30):12248–12253. https://doi.org/10.1073/pnas.1202835109.

Carvalho AF, Rocha DAC, McIntyre RS et al. Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. J Psychiatr Res 2014;59:28–37. https://doi.org/10.1016/j.jpsychires.2014.08.002.

Syk M, Ellstrom S, Mwinyi J et al. Plasma levels of leptin and adiponectin and depressive symptoms in young adults. Psychiatry Res. 2019;272:1–7. https://doi.org/10.1016/j.psychres.2018.11.075.

Formolo DA, Lee TH-Y, Yau S-Y. Increasing adiponergic system activity as a potential treatment for depressive disorders. Mol Neurobiol. 2019;56(12):7966–7976. https://doi.org/10.1007/s12035-019-01644-3.

The authors declare that there are no conflicts of interest present.